HC Wainwright Has Bearish Forecast for MLYS FY2026 Earnings

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) – Equities research analysts at HC Wainwright lowered their FY2026 earnings estimates for Mineralys Therapeutics in a report released on Thursday, November 5th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($4.56) for the year, down from their previous estimate of ($4.40). HC Wainwright has a “Buy” rating and a $56.00 price target on the stock. The consensus estimate for Mineralys Therapeutics’ current full-year earnings is ($4.60) per share. HC Wainwright also issued estimates for Mineralys Therapeutics’ Q4 2026 earnings at ($0.64) EPS and FY2027 earnings at ($2.35) EPS.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.09).

Several other analysts also recently issued reports on MLYS. Zacks Research upgraded Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, September 11th. UBS Group assumed coverage on Mineralys Therapeutics in a research note on Sunday, October 11th. They set a “neutral” rating and a $29.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, October 15th. Finally, Wall Street Zen lowered Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Mineralys Therapeutics has an average rating of “Hold” and a consensus target price of $45.50.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $15.81 on Monday. The company has a debt-to-equity ratio of 0.18, a current ratio of 34.46 and a quick ratio of 34.46. The company’s fifty day simple moving average is $23.58 and its 200-day simple moving average is $26.54. Mineralys Therapeutics has a 52 week low of $14.91 and a 52 week high of $47.65.

Hedge Funds Weigh In On Mineralys Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MLYS. ACT Capital Partners L.P. acquired a new position in shares of Mineralys Therapeutics in the 3rd quarter valued at approximately $2,196,000. Aberdeen Group plc boosted its stake in shares of Mineralys Therapeutics by 29.8% during the 3rd quarter. Aberdeen Group plc now owns 894,403 shares of the company’s stock valued at $22,476,000 after buying an additional 205,168 shares during the last quarter. Ethic Inc. purchased a new position in shares of Mineralys Therapeutics during the 3rd quarter valued at approximately $269,000. Alps Advisors Inc. grew its position in shares of Mineralys Therapeutics by 31.7% during the third quarter. Alps Advisors Inc. now owns 117,144 shares of the company’s stock worth $2,944,000 after buying an additional 28,168 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Mineralys Therapeutics during the third quarter worth approximately $114,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Eric Warren sold 7,438 shares of the company’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $28.12, for a total value of $209,156.56. Following the completion of the transaction, the insider directly owned 38,400 shares in the company, valued at approximately $1,079,808. This represents a 16.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian Slingsby sold 104,320 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $28.81, for a total transaction of $3,005,459.20. Following the sale, the director directly owned 7,805,718 shares of the company’s stock, valued at approximately $224,882,735.58. The trade was a 1.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 197,195 shares of company stock valued at $5,403,069. 18.94% of the stock is currently owned by company insiders.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing treatments for hypertension and other cardiovascular and kidney conditions associated with excess aldosterone. The company is based in Radnor, Pennsylvania, and was founded in 2019.

Its lead product candidate, lorundrostat, is an investigational oral inhibitor of aldosterone synthase. Mineralys is studying the drug as a potential treatment for difficult-to-control hypertension and conditions related to excess aldosterone; it is not an approved or marketed therapy.

The company’s work is focused on drug development and clinical research, with trials primarily conducted in the United States.